Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly

J Braun; Neil J McHugh; A Singh; J S Wajdula; R Sato

doi:10.1093/rheumatology/kem069

Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly

J Braun, Neil J McHugh, A Singh, J S Wajdula, R Sato

Research output: Contribution to journal › Article › peer-review

79 Citations (SciVal)

Abstract

The more convenient etanercept 50 mg QW dose regimen significantly improves function and QOL in patients with AS, similarly to the standard dosing of 25 mg BIW, supporting its use for AS therapy.

Original language	English
Pages (from-to)	999-1004
Number of pages	6
Journal	Rheumatology
Volume	46
Issue number	6
DOIs	https://doi.org/10.1093/rheumatology/kem069
Publication status	Published - 2007

Access to Document

10.1093/rheumatology/kem069

Cite this

@article{c28a113be74b405c99655eea99c18e38,

title = "Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly",

abstract = "The more convenient etanercept 50 mg QW dose regimen significantly improves function and QOL in patients with AS, similarly to the standard dosing of 25 mg BIW, supporting its use for AS therapy.",

author = "J Braun and McHugh, {Neil J} and A Singh and Wajdula, {J S} and R Sato",

year = "2007",

doi = "10.1093/rheumatology/kem069",

language = "English",

volume = "46",

pages = "999--1004",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly

AU - Braun, J

AU - McHugh, Neil J

AU - Singh, A

AU - Wajdula, J S

AU - Sato, R

PY - 2007

Y1 - 2007

N2 - The more convenient etanercept 50 mg QW dose regimen significantly improves function and QOL in patients with AS, similarly to the standard dosing of 25 mg BIW, supporting its use for AS therapy.

AB - The more convenient etanercept 50 mg QW dose regimen significantly improves function and QOL in patients with AS, similarly to the standard dosing of 25 mg BIW, supporting its use for AS therapy.

UR - http://dx.doi.org/10.1093/rheumatology/kem069

U2 - 10.1093/rheumatology/kem069

DO - 10.1093/rheumatology/kem069

M3 - Article

SN - 1462-0324

VL - 46

SP - 999

EP - 1004

JO - Rheumatology

JF - Rheumatology

IS - 6

ER -

Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly

Abstract

Access to Document

Other files and links

Fingerprint

Cite this